Dr. Julia Levy Accepts Position On ProtoKinetix Inc. (PKTX.OB)' Business And Scientific Advisory Board

VANCOUVER, British Columbia--(BUSINESS WIRE)--ProtoKinetix (OTCQB:PKTX) (www.protokinetix.com) is pleased to announce that Julia Levy, PhD, co-founder of QLT, Inc., has accepted the position as head of its Business and Scientific Advisory Board. 

Discoveries made by her and colleagues at the University of British Columbia in the field of photodynamic therapy were the basis of the first medical treatment of macular degeneration, a leading cause of blindness among the elderly, a treatment was developed by QLT, Inc. She served first as Chief Scientific Officer and later as Chief Executive Officer of QLT.

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.